MDS: Clinical Trials

5 trials for MDS, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 unknown. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Unknown 5
Phase 22Unknown 2

Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS
XZB-0004 - AML, MDS
Phase 1UnknownXuanzhu Biopharmaceutical Co., Ltd.822023-02-012023-02-23
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
APG-115, 5-azacitidine - AML, Acute Myeloid Leukemia
Phase 1 / Phase 2UnknownAscentage Pharma Group Inc.692020-12-042024-02-01
Study of APVO436 in Patients With AML or MDS
APVO436 - AML, MDS
Phase 1UnknownAptevo Research and Development LLC1362018-12-132022-02-10
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
Decitabine, Arsenic Trioxide - P53 Mutation, Myeloid Malignancy
Phase 1UnknownRuijin Hospital52018-01-102022-11-04
A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS
Deferasirox, Vitamin D and Azacitidine - MDS
Phase 1 / Phase 2UnknownGroupe Francophone des Myelodysplasies502013-02-012018-01-10

Narrower conditions

Leukemia, Myeloid, Acute (2)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Myelodysplastic Syndromes (1)

Broader conditions

Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Leukemia (2)  ·  Leukemia, Myeloid (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Bone Marrow Diseases (1)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Myelodysplastic-Myeloproliferative Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Azacitidine (2)  ·  Arsenic Trioxide (1)  ·  Decitabine (1)  ·  Deferasirox (1)  ·  Vitamin D (1)

Sponsors

Aptevo Research and Development LLC (1)  ·  Ascentage Pharma Group Inc. (1)  ·  Groupe Francophone des Myelodysplasies (1)  ·  Ruijin Hospital (1)  ·  Xuanzhu Biopharmaceutical Co., Ltd. (1)

Countries

China (2)  ·  United States (2)  ·  Belgium (1)  ·  France (1)

Top investigators

Felipe Suarez, MD (1)  ·  Olivier Hermine, MD (1)  ·  Pierre Fenaux, MD (1)  ·  Sujiang Zhang, MD, PhD (1)  ·  Yifan Zhai, MD, PhD (1)

Results publications

PMID 34439266, PMID 34771451